ORCID Profile
0000-0002-1620-6105
Current Organisation
Université de Rouen UFR STAPS
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 04-2007
Publisher: The Endocrine Society
Date: 06-2009
DOI: 10.1210/JC.2008-2313
Abstract: In patients with differentiated thyroid carcinoma, postablation (131)I scintigraphy aims to detect residual neck disease and distant metastases, usually found in lungs and bones. New hybrid single-photon emission computed tomography/computed tomography (SPECT-CT) cameras that permit functional and anatomical image fusion may improve its clinical relevance. Our objective was to test the added value of neck and thorax SPECT-spiral CT to whole-body scan (WBS) in postablation (131)I scintigraphy. This was a single-referral-center prospective study with a median follow-up of 21 months. Postablation (131)I WBS and neck and thorax SPECT-CT were performed in 55 consecutive patients treated in 2006. WBS and SPECT-CT data were blindly reviewed, scored negative (benign), positive (malignant), or indeterminate and were correlated to the patient outcome. At patient level, WBS and SPECT-CT were negative in 67 and 78% of patients, positive in 4 and 15%, and indeterminate in 29 and 7%, respectively. Overall, nine patients (16%) presented treatment failure (persistent or recurrent disease) 1-16 months after radioiodine ablation. In the 16 patients with indeterminate WBS, negative SPECT-CT ruled out suspicion of disease in nine of nine patients, and positive SPECT-CT confirmed malignant lesions in four of five patients. Positive SPECT-CT predicted treatment failure better than positive WBS (McNemar's test, P = 0.03). This study demonstrates the complementary role of neck and thorax SPECT-CT to WBS in postablation (131)I scintigraphy. Because SPECT-CT allows one to confirm or to rule out residual disease in most cases where WBS remains indeterminate, we recommend its use when available.
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 03-2012
Publisher: Oxford University Press (OUP)
Date: 06-2011
DOI: 10.1530/EJE-11-0156
Abstract: Neck and thorax single photon emission computed tomography with computed tomography (SPECT–CT) improves the reliability of postablation 131 I whole-body scan (WBS) for differentiated thyroid cancer (DTC). The aim of this study was to assess the prognostic value for persistent or recurrent disease of postablation 131 I scintigraphy combining WBS and neck and thorax SPECT–CT with that of the previously known predictive factors. This is a single referral center prospective study with a median follow-up of 29 months. Postablation 131 I WBS and neck and thorax SPECT–CT were performed in 170 consecutive patients treated between 2006 and 2008. Stimulated serum thyroglobulin (Tg) and anti-thyroglobulin antibodies (TgAb) levels were measured. The impact on disease-free survival of age gender postablation 131 I scintigraphy stimulated serum Tg level T, N, and M status and macroscopic lymph node involvement was assessed by univariate and multivariate analyses. Persistent or recurrent disease was observed in 32 (19%) patients. In the whole group of patients, only positive WBS with SPECT–CT was related to an increased risk of persistent or recurrent disease (hazards ratio (HR)=65.21, 95% confidence interval (CI)=26.03–163.39, P .0001). In patients without TgAb ( n =146), both positive WBS with SPECT–CT (HR=18.86, 95% CI=5.02–70.85, P .0001) and serum Tg level ≥58 ng/ml (HR=4.42, 95% CI=1.18–16.53, P =0.0271) were associated with an increased risk. In patients with DTC, the cross analysis of postablation 131 I scintigraphy with neck and thorax SPECT–CT and stimulated serum Tg level enables early assessment of the risk of persistent or recurrent disease.
Publisher: Springer Science and Business Media LLC
Date: 13-07-2012
No related grants have been discovered for Natacha Heutte.